|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2003-9-8
|
|
pubmed:abstractText |
Meta-analyses of the prevention of major vascular events by aspirin suggest therapeutic equivalence of all dosages. However, the optimal dosage still remains problematic, and a recent trial found aspirin 160 mg/day to be more effective than 80 mg/day for secondary prevention of ischaemic stroke.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0312-5963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1059-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12959636-Adult,
pubmed-meshheading:12959636-Area Under Curve,
pubmed-meshheading:12959636-Aspirin,
pubmed-meshheading:12959636-Blood Platelets,
pubmed-meshheading:12959636-Chromatography, High Pressure Liquid,
pubmed-meshheading:12959636-Cross-Over Studies,
pubmed-meshheading:12959636-Dose-Response Relationship, Drug,
pubmed-meshheading:12959636-Epoprostenol,
pubmed-meshheading:12959636-Female,
pubmed-meshheading:12959636-Fibrinolytic Agents,
pubmed-meshheading:12959636-Humans,
pubmed-meshheading:12959636-Male,
pubmed-meshheading:12959636-Platelet Aggregation Inhibitors,
pubmed-meshheading:12959636-Salicylates,
pubmed-meshheading:12959636-Tablets, Enteric-Coated,
pubmed-meshheading:12959636-Thromboxane B2,
pubmed-meshheading:12959636-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
|
|
pubmed:affiliation |
Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy. ccerletti@rm.unicatt.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
